- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Management of Recurrent C Difficile Infections in the Future
Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
EP: 1.The Role of Testing for C Difficile in Clinical Practice
EP: 2.Utilizing Antibiotics in Treatment of C Difficile
EP: 3.Examining FMT for Patients With Recurrent C Difficile infections
EP: 4.Exploring Rebyota for Recurrent C Difficile Infections
EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
EP: 7.Management of Recurrent C Difficile Infections in the Future
EP: 8.Key Background Information on Recurrent C. Difficile Infections
EP: 9.Importance of Early Detection of Recurrent C Difficile Infections
EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
EP: 11.Diagnosis of Recurrent C Difficile Infections
EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections
EP: 13.Unmet Needs With Recurrent C Difficile Infections
Video content above is prompted by the following:
- How do you see the management of recurrent C difficile infections moving forward?
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood
February 28th 2025Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), but those who had more siblings reported being more ready to transition to adult life.
Read More
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
